Viva Biotech's 15-Year Commitment to European Drug Discovery and Collaboration

Celebrating 15 Years of Drug Discovery Collaboration

Viva Biotech, a prominent player in drug discovery, has proudly marked over 15 years of dedicated partnership with Europe's biopharmaceutical community. As the sector undergoes substantial evolution, the significance of strong collaborative ties has amplified immensely. Viva Biotech has embedded itself as more than a service provider; it has emerged as a reliable partner that integrates seamlessly with its clients’ teams, providing continuous support and ingenuity through the entire drug discovery process.

Operational Stability Amidst Change

In recent times, many biopharmaceutical companies have faced disruptions due to industry changes. However, Viva Biotech has successfully maintained a consistent operational foundation. Having grown alongside European partners for over fifteen years, it has become a trusted ally during these turbulent times. With its robust infrastructure and experienced teams situated in the UK, Viva Biotech ensures that its partners receive localized support that is both responsive and effective, enabling them to navigate the complexities of drug discovery efficiently.

Trust and Reliability in Drug Development

Trust is paramount in the pharmaceutical sector, and Viva Biotech places utmost importance on building long-term relationships with its clients. By consistently delivering results on critical scientific milestones, the company fortifies its reputation as an indispensable resource. Through a blend of technical expertise and an understanding of scientific goals, Viva Biotech stands by its partners every step of the way.

Innovative Platforms for Enhanced Discovery

To further support its partners, Viva Biotech has committed to broadening its integrated platform capabilities. This expansion encompasses various disciplines, enabling the transition from early drug discovery phases to candidate nomination with heightened confidence.

Diverse Therapeutic Modalities

Viva Biotech’s integrated workflow incorporates various therapeutic modalities. By combining Structure-Based Drug Discovery (SBDD), cryo-electron microscopy (cryo-EM), and advanced medicinal chemistry techniques, it adeptly supports projects spanning traditional small molecules as well as modern approaches like peptides and proximity-inducing compounds. This versatility is crucial for reducing uncertainties and ensuring smooth transitions across different stages of drug development.

Advanced AI Integration

One of the standout features of Viva Biotech's approach is its advanced AI-enabled platforms, which have been integrated into their discovery workflows. This technological enhancement has already influenced nearly 200 projects, creating pathways that are more efficient and bolstered by data-driven decision-making.

Structural Insights and Industry Knowledge

With comprehensive expertise built on the examination of over 98,000 protein structures, over 200 cryo-EM structures, and extensive insights into membrane protein targets, Viva Biotech equips its partners with invaluable knowledge. This depth of understanding offers significant advantages as drug candidates are developed and optimized for market readiness.

Supporting Comprehensive Development

Viva Biotech has employed an integrated strategy extending from discovery to commercialization. By offering CMC (Chemistry, Manufacturing and Controls) and CDMO (Contract Development and Manufacturing Organization) services, it ensures that projects are supported throughout the commercial pathway, culminating in successful process performance qualification. As of now, this holistic approach has facilitated 295 drug projects moving into crucial CMC stages.

The Path Forward

Reflecting on the past 15 years highlights a narrative punctuated by groundbreaking scientific accomplishments and a commitment to long-term partnerships. As Viva Biotech embarks on the next chapter, it remains dedicated to nurturing deeper relationships with drug discovery partners, fueling innovation and driving change within the European biopharmaceutical sector for many more years ahead.